Orion Oyj (0M2O.IL)

35,87 -0,54 (-1,48%) Börsenschluss: 05:03PM BST

Orion Oyj

Orionintie 1A
Espoo 02200
Finland
358 10 4261
https://www.orion.fi

Sektor(en): Healthcare
Branche: Drug Manufacturers - General
Vollzeitmitarbeiter: 3.657

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Liisa Hurme	Pres, CEO & Chairman of Exec. Management Board	106,13k	N/A	1967
Mr. Jari Karlson M.Sc., M.Sc. (Econ.)	CFO & Member of the Exec. Management Board	N/A	N/A	1961
Mr. Olli Huotari Ll.M.	Sr. VP of Corp. Functions, Gen. Counsel, Sec. & Member of Exec. Management Board	N/A	N/A	1966
Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.)	Sr. VP of Generics and Consumer Health Bus. Division & Member of the Exe. Mgmt. Board	N/A	N/A	1966
Ms. Virve Laitinen M.Sc. (Tech.), MBA	Sr. VP of Corp. Strategy and Program Mgmt. Grp. Level Function & Member of the Exe. Mgmt. Board	N/A	N/A	1972
Prof. Outi Vaarala M.D., Ph.D.	Sr. VP of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. Board	N/A	N/A	1962
Mr. Juhani Kankaanpaa	Sr. VP of Global Operations & Member of Exec. Management Board	N/A	N/A	N/A
Mr. Niclas Lindstedt EMBA, M.Sc.	Sr. VP of Animal Health Bus. Division & Member of the Exe. Mgmt. Board	N/A	N/A	N/A
Mr. Hao Pan M.Sc.	Sr. VP of the Branded Products Bus. Division & Member of the Exe. Mgmt. Board	N/A	N/A	1971
Mr. Tuukka Hirvonen M.Sc.(Soc.)	Investor Relations & Financial Communications Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Precedex for intensive care sedative, as well as Fareston for breast cancer. The company also offers Salmeterol/fluticasone Easyhaler; Budesonide/formoterol Easyhaler; Formoterol Easyhaler; Budesonide Easyhaler; Beclomet Easyhaler; and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic and proprietary drugs, as well as provides contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. The company serves primarily healthcare services providers and professional, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Further, it has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. The company was founded in 1917 and is headquartered in Espoo, Finland.

Corporate Governance

Orion Oyjs ISS Governance QualityScore, Stand 1. Oktober 2023, lautet 3. Die grundlegenden Scores sind Audit: 4, Vorstand: 2, Shareholderrechte: 10, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.